Shows / Multiple Myeloma Hub
Multiple Myeloma Hub
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy for more information.
Episodes
- Multiple Myeloma Hub
How is belantamab mafodotin currently used in clinical practice for MM?
The Multiple Myeloma Hub spoke with Fredrik Schjesvold, Oslo University Hospital, Oslo, NO. We asked how belantamab mafodotin is currently used in clinical…
- Multiple Myeloma Hub
How are ocular toxicities associated with belantamab mafodotin managed in MM?
The Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-Universität Würzburg, DE. We asked, How are ocular toxicities associated…
- Multiple Myeloma Hub
Targeting FcRH5 in MM: Rationale and emerging dual-targeting strategies
The Multiple Myeloma Hub was pleased to speak with Adam Cohen, University of Pennsylvania, Philadelphia, US. We asked about the rationale for targeting FcRH5…
- Multiple Myeloma Hub
IMS 2026 | CARTITUDE-2 Cohort A: ≥5-year remission and survival with cilta-cel in RRMM
During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with…
- Multiple Myeloma Hub
IMS 2026 | UKMRA ProMMise D interim results: VRAT-guided belantamab mafodotin dosing in RRMM
During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with…
- Multiple Myeloma Hub
How to optimize outpatient delivery of bispecific antibody therapy for MM
The Multiple Myeloma Hub spoke with Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK. We asked how to optimize outpatient delivery of bispecific…
- Multiple Myeloma Hub
Belantamab mafodotin in RRMM: Latest updates and practical considerations
The Multiple Myeloma Hub spoke with Christoph Renner, University of Basel, Basel, CH. We asked about the use of belantamab mafodotin-based combination therapy…
- Multiple Myeloma Hub
How to manage toxicities associated with bispecific antibody therapy for MM in community practice
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the management of toxicities associated with…
- Multiple Myeloma Hub
How to transition patients to community-based bispecific antibody therapy
The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about transitioning patients to community-based bispecific antibody…
- Multiple Myeloma Hub
EHA2026 | DREAMM-8: Early RRMM and sustained MRD-negativity subgroup analyses
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Meral Beksaç, Istinye…
- Multiple Myeloma Hub
EHA2026 | What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM?
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Binod Dhakal, Medical…
- Multiple Myeloma Hub
Integrating BCMA-directed bispecific antibodies into the treatment paradigm for MM
During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss the integration of B-cell maturation antigen…
- Multiple Myeloma Hub
Strategies for managing belantamab mafodotin-associated ocular toxicities
During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss strategies for managing belantamab…
- Multiple Myeloma Hub
EHA2026 | What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM?
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Vania Tietsche de Moraes…
- Multiple Myeloma Hub
What’s on the horizon for relapsed/refractory MM in 2026?
The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What’s on the horizon for the treatment…
- Multiple Myeloma Hub
CELMoDs for the treatment of newly diagnosed and HR smoldering MM
The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the emerging role of cereblon E3 ligase…
- Multiple Myeloma Hub
CELMoDs for the treatment of relapsed/refractory MM
The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about cereblon E3 ligase modulators (CELMoDs) for the…
- Multiple Myeloma Hub
CELMoDs: Mechanism of action and immunomodulatory activity in MM
The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the mechanism of action and immunomodulatory…
- Multiple Myeloma Hub
The patient experience: Treatment with BCMA-directed therapies in relapsed MM
On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in…
- Multiple Myeloma Hub
Optimizing BCMA-directed therapies: Balancing efficacy, safety, and PROs
On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in…
- Multiple Myeloma Hub
Overview of BCMA-directed therapies for multiple myeloma
On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in…
- Multiple Myeloma Hub
Quality-of-life considerations with BCMA‑directed therapies for MM
On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in…
- Multiple Myeloma Hub
Symposium | Practical considerations when sequencing novel agents and managing AEs with BCMA-directed therapies
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from…
- Multiple Myeloma Hub
Symposium | Future directions with novel and established BCMA-DT in the MM treatment paradigm
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from…
- Multiple Myeloma Hub
Symposium | Real-world insights and clinical experience with BCMA‑directed therapies
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into…
- Multiple Myeloma Hub
Symposium | BCMA-directed therapies in MM: Current applications and the evolving clinical landscape
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into…
- Multiple Myeloma Hub
What are the latest updates from the phase I trial of P-BCMA-ALLO1 for the treatment of RRMM?
The Multiple Myeloma Hub spoke with Mehmet Hakan Kocoglu, University of Maryland, Baltimore, US. We asked, What are the latest updates from the phase I trial…
- Multiple Myeloma Hub
Improving access to CAR T-cell therapy for eligible patients with MM
During the Multiple Myeloma Hub Steering Committee Meeting in November 2025, key opinion leaders met to discuss improving access to chimeric antigen receptor…
- Multiple Myeloma Hub
ASH 2025 | CARTITUDE-4: Long-term PFS outcomes with cilta-cel for standard-risk RRMM
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Multiple Myeloma Hub was pleased to…
- Multiple Myeloma Hub
Clinical experience with belantamab mafodotin: Management strategies for ocular toxicity
The Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about clinical experience with belantamab mafodotin, with a…
- Multiple Myeloma Hub
MIDAS: MRD-driven strategy after Isa-KRd induction in ND ASCT-eligible MM
The Multiple Myeloma Hub spoke with Paul Richardson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, US. We asked…
- Multiple Myeloma Hub
How might the clinical development of CELMoDs impact the treatment paradigm for MM?
The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, How might the clinical development of cereblon E3…
- Multiple Myeloma Hub
CARTITUDE-2: Cilta-cel ± Len maintenance for MM with suboptimal response to ASCT
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the latest findings from the updated follow-up…
- Multiple Myeloma Hub
Evolving diagnostic criteria for high-risk smoldering MM
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, Spain. We asked about the evolving diagnostic criteria…
- Multiple Myeloma Hub
What combination regimens including BiTEs are being evaluated for the treatment of RRMM?
The Multiple Myeloma Hub spoke with Ravi Vij, Washington University, St. Louis, US. We asked, What combination regimens including bispecific T-cell engagers…
- Multiple Myeloma Hub
Risk stratification and prognosis in smoldering MM
The Multiple Myeloma Hub spoke to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked about risk stratification and prognosis in smoldering…
- Multiple Myeloma Hub
What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for MM?
The Multiple Myeloma Hub spoke with Alexander Lesokhin, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What combination regimens containing…
- Multiple Myeloma Hub
How can neurotoxicity associated with CAR T-cell therapy in MM be managed?
The Multiple Myeloma Hub spoke with Peter Forsberg, Colorado Blood Cancer Institute, Denver, US. We asked, How can neurotoxicity associated with chimeric…
- Multiple Myeloma Hub
What might be the future applications for BCMA-directed bispecific antibodies in MM and other PCD?
The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What might be the future applications…
- Multiple Myeloma Hub
What is the rationale for early intervention in high-risk smoldering MM?
The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about the future perspectives for the treatment of patients with…
- Multiple Myeloma Hub
How are BCMA-directed bispecific antibodies currently utilized in real-world practice for MM?
The Multiple Myeloma Hub was pleased to speak with Hang Quach, St Vincent’s Hospital Melbourne and University of Melbourne, Melbourne, AU. We asked, How are…
- Multiple Myeloma Hub
MRD in MM: Implications for clinical practice and trial design
During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss the implications of measurable residual disease…
- Multiple Myeloma Hub
Targeting XPO1 for the treatment of MM: Real-world evidence
During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss exportin 1 (XPO1) as a target for the treatment of…
- Multiple Myeloma Hub
How to incorporate novel therapies into the treatment paradigm for early RRMM?
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were…
- Multiple Myeloma Hub
What are the future perspectives for anti-CD38 mAbs in the treatment of MM?
In this interview, Hermann Einsele discusses the future perspectives of anti-CD38 antibodies, highlighting their role in first-line treatment for both…
- Multiple Myeloma Hub
What are the current treatment recommendations and unmet needs in early RRMM?
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were…
- Multiple Myeloma Hub
What is the rationale for treating early RRRM with targeted therapies?
The Multiple Myeloma Hub spoke to Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What is the rationale for treating early…
- Multiple Myeloma Hub
What is the impact of belantamab mafodotin on QoL in patients with MM?
The Multiple Myeloma Hub spoke to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What is the impact of belantamab mafodotin…
- Multiple Myeloma Hub
What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma?
The Multiple Myeloma Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the impact of elranatamab on…
- Multiple Myeloma Hub
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled…
- Multiple Myeloma Hub
Integrating cilta-cel into earlier lines of therapy: Rationale and latest data from CARTITUDE-2 and CARTITUDE-4
Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy, which is one of only two…
- Multiple Myeloma Hub
Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled…
- Multiple Myeloma Hub
Teclistamab: real-world safety and efficacy
During the 65th American Society of Hematology Annual Meeting and Exposition, Dima presented results from a retrospective analysis to evaluate the real-world…
- Multiple Myeloma Hub
Infections associated with bispecific antibodies
During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss key considerations regarding infections associated…
- Multiple Myeloma Hub
CAR T-cell therapies in clinical practice
During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current use of CAR T-cell therapies in clinical…
Multiple Myeloma HubHow to select maintenance therapies post-ASCT for patients with high-risk MM?
The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US, and Naresh Bumma, The Ohio State University, Columbus, US. We asked…
Multiple Myeloma HubShould risk-adapted MM treatment be informed by age or frailty status?
The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM treatment be informed by age or…
- Multiple Myeloma Hub
How is the immune reconstitution in patients who stop therapy after achieving MRD negativity?
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Timothy Schmidt…
- Multiple Myeloma Hub
What are the main discrepancies between MM treating centers in Brazil?
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes…
- Multiple Myeloma Hub
What are the initial data of dara-CyBorD in patients with extramedullary disease?
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ankara…